More than just a potential

breakthrough treatment

for many cancers

June 2015

22

Critical Outcome Technologies Inc.

Rapidly developing targeted therapies to better meet the needs of patients

TSX-V: COT

OTCQB: COTQF

3

Highlights

1

2

3

COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015

CHEMSAS – proprietary drug discovery engine using machine-based learning

Strong pipeline of opportunities in oncology and other therapeutic areas

4

COTI-2: a promising advance

Potential breakthrough treatment for many cancers

Effective against many common cancers with a p53 gene mutation

> 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)

5

COTI-2 background

N

NNH

S

N

N

N

3rd generation Thiosemicarbazone

A small molecule discovered by our CHEMSAS process

Engineered for low toxicity and easily synthesized in 3 steps

Demonstrates strong in vitro and in vivo activity

5

6

COTI-2: first- and best-in-class potential

Novel p53-dependent mechanism of action

Orally bio-available and effective at low dose

Low toxicity in preclinical development

Opportunity for single agent and combination therapy

Strong IP protection in place

7

COTI-2 and tumor volumes

Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control

8

COTI-2 reduces p53 resistant protein levels

COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV-112D cells likely by inducing a conformational change

•(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)

Mutant p53 Levels in the presence/absence of COTI-2

0

20

40

60

80

100

TOV-112D H460

Me

an F

luo

resc

en

ce In

ten

sity

(A

rbit

rary

Un

its)

Cell Line

Control

COTI-2

*

9

COTI-2: effects on p53 protein levels

COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein

•(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)

Wild-type p53 Levels in the Presence/Absence of COTI-2

0

20

40

60

80

100

120

TOV-112D H460

Me

an F

luo

resc

en

ce In

ten

sity

(A

rbit

rary

Un

its)

Cell Line

Control

COTI-2

*

10

MD Anderson relationship

10

Confirmed COTI-2’s novel p53 dependent MOA

Confirmed selective & potent anti-cancer activity

Identified effective dosage 60% lower than in prior animal experiments

11

COTI-2: the pathway to the clinic

Granted orphan drug status for ovarian cancer by FDA in June 2014

Completed final pre-clinical studies

Signed LOI with MD Anderson for Phase 1 clinical development

Grant of Investigational New Drug status in May 2015

Commence Phase 1 clinical trial in 3rd quarter of calendar 2015

12

COTI-2: next steps

12

Complete Phase 1: 46 patients in gynecologic cancers

Expand indications and combination therapies

Phase 2: add value – create partnerships

1313

Proprietary, machine learning (AI) based drug discovery platform technology

Big Data analysis solutions

Building a robust pipeline with CHEMSAS®

14

Costly failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’

Increased probability of clinical & commercial success

Database driven computational replication of traditional ‘wet lab’ drug discovery process

14

Advantages of CHEMSAS®

15

Drugs in our pipeline

TherapyLibrary /Compound

Target CHEMSAS Lead Selection

Synthesis Preclinical Phase 1

Oncology

COTI-2

AML

Colon

Small Cell Lung Cancer Library

COTI-219

COTI-4

COTI-58

6 other leads

Plus projects for MRSA, Multiple sclerosis, Alzheimer’s, and HIV Integrase Inhibitors

16

Summary

1

2

3

COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015

CHEMSAS – proprietary drug discovery engine using machine-based learning

Strong pipeline of opportunities in oncology and other therapeutic areas

17

When used anywhere in this presentation, whether oral or written, the words expects, believes,anticipates, estimates and similar expressions are intended to identify forward-lookingstatements. Forward-looking statements may include statements addressing future financial andoperating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events.Such statements are subject to risks and uncertainties including, but not limited to, thesuccessful implementation of COTI’s strategic plans, the acceptance of new products, theobsolescence of existing products, the resolution of potential patent issues, competition,changes in economic conditions, and other risks described in COTI’s public documents such aspress releases and filings with the Toronto Stock Exchange and the Ontario SecuritiesCommission.

All forward-looking statements are qualified in their entirety by the cautionary statementsincluded in this document and such filings. These risks and uncertainties could cause actualresults to differ materially from results expressed or implied by forward-looking statementscontained in this presentation. These forward-looking statements speak only as of the date ofthis presentation.

Disclaimer

Follow CriticalOutcome on Twitter,

Facebook, YouTube and SlideShare